Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Clin Cancer Res. 2011 Apr 11;17(11):3706–3715. doi: 10.1158/1078-0432.CCR-10-3082

Figure 4. AZD7762 increases pS345 Chk1 in response to gemcitabine.

Figure 4

MiaPaCa-2 xenografts were treated with gemcitabine (120 mg/kg) on day 0 and AZD7762 (25 mg/kg) on days 0 and 1 (A, C). Alternatively, Patient-J-derived xenografts were treated with gemcitabine (60 mg/kg) on day 0 and AZD7762 (20 mg/kg) on days 0 and 1 (B, D). Tumors were harvested on day 1, following the last dose of AZD7762 and prepared for immunoblotting (A–B) or immunohistochemistry (C–D). Data are from a single experiments representative of 3 – 4 tumors per treatment group.